Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure

Bocchi, E A; Moura, Lídia Zytynski; Guimarães, Guilherme; Souza, Germano Emílio Conceição; Ramires, José Antônio Franchini

doi:10.1016/j.ijcard.2005.06.068

Cited by 16 publications

(15 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent study, high doses (8IU) of growth hormone improved heart function (measured as left ventricular ejection fraction) and clinical classification markers (Classification from NYHA) in 6 patients with CC and unstable decompensated CHF (91). More studies are needed to confirm these results.…”

Section: Central and Genetic Approachesmentioning

confidence: 97%

Metabolic and immunologic derangements in cardiac cachexia: where to from here?

Strassburg¹,

Anker

2006

Heart Fail Rev

View full text Add to dashboard Cite

The onset of cardiac cachexia is characterized by a defined severe weight loss in patients with advanced chronic heart failure and it predicts an increased mortality in these patients. Recent studies with potential therapeutics investigated the effects and efficiency of beta-blockers, ghrelin, or ghrelinagonists in cachexia. These and other new studies, like the influence of heart transplantation on cardiac cachexia, give prospect into potential therapeutic options in the future. General aim of the treatment strategy is to prevent the onset and retard the progress of cachexia. This could be achieved by modifying the metabolic, neurohormonal and immune system abnormalities, e.g. with beta-blockers and angiotensinconverting enzyme inhibitors. However, these alterations interact in a complex pathophysiological process, which is supposed to end in a vicious circle and thereby the wasting process is further promoted. To interrupt this, an early start of therapy is important to decelerate the development of cardiac cachexia. Many further investigations are needed to find out more about the pathophysiological pathways, to confirm the previous results, and to evaluate new therapeutics.

show abstract

Section: Central and Genetic Approachesmentioning

confidence: 97%

Metabolic and immunologic derangements in cardiac cachexia: where to from here?

Strassburg¹,

Anker

2006

Heart Fail Rev

View full text Add to dashboard Cite

show abstract

“…São necessários grandes estudos randomizados para avaliação da segurança e eficácia em longo prazo 289,290 .…”

Section: Hormônio Do Crescimentounclassified

Atualização da Diretriz Brasileira de Insuficiência Cardíaca Crônica - 2012

2012

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

“…As well as inducing muscle hypertrophy, GH can also modulate cell muscle differentiation, proliferation, and survival, which can be directly mediated or mediated by insulin-like growth factor-1 (IGF-1) [12][13][14]. Although studies on GH treatment for heart failure patients have shown controversial results [15][16][17][18], peripheral GH action suggests a potential role to beneficially modulate skeletal muscle structure and function during HF. In fact, in monocrotaline treated rats, a short-term model of heart failure, GH prevented both skeletal muscle atrophy and a shift from slow type I to fast type II fiber [13,19].…”

Section: Introductionmentioning

confidence: 99%